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Diamond-Blackfan anemia (DBA) is a rare inherited bone marrowfailure disorder linked predominantly to ribosomal protein genemutations. Here the European DBA consortium reports novel
mutations identified in the RPL15 gene in 6 unrelated individuals diag-
nosed with DBA. Although point mutations have not been previously
reported for RPL15, we identified 4 individuals with truncating muta-
tions p.Tyr81* (in 3 of 4) and p.Gln29*, and 2 with missense variants
p.Leu10Pro and p.Lys153Thr. Notably, 75% (3 of 4) of truncating muta-
tion carriers manifested with severe hydrops fetalis and required
intrauterine transfusions. Even more remarkable is the observation that
the 3 carriers of p.Tyr81* mutation became treatment-independent
between four and 16 months of life and maintained normal blood counts
until their last follow up. Genetic reversion at the DNA level as a poten-
tial mechanism of remission was not observed in our patients. In vitro
studies revealed that cells carrying RPL15mutations have pre-rRNA pro-
cessing defects, reduced 60S ribosomal subunit formation, and severe
proliferation defects. Red cell culture assays of RPL15-mutated primary
erythroblast cells also showed a severe reduction in cell proliferation,
delayed erythroid differentiation, elevated TP53 activity, and increased
apoptosis. This study identifies a novel subgroup of DBA with muta-
tions in the RPL15 gene with an unexpected high rate of hydrops fetalis
and spontaneous, long-lasting remission.  
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ABSTRACT
Introduction
Diamond-Blackfan anemia (DBA) (OMIM# 105650) is an inherited bone mar-
row failure disorder that typically manifests in children under the age of one year.
While the central phenotype is pure red cell aplasia, developmental delay and a
number of physical malformations are also linked to
DBA.1 These include (but are not limited to) craniofacial
malformations, growth retardation, abnormalities in the
extremities, heart defects, as well as urogenital defects.2,3
While most patients (>90%) are diagnosed within the
first year of life, a minority present with anemia at birth.
Hydrops fetalis due to severe intrauterine anemia is con-
sidered a very rare manifestation of DBA.4 To date, a
total of 10 cases of DBA-associated hydrops have been
reported in single cases.5-13  The clinical outcome of these
patients was poor as compared to typical DBA (3
patients died perinatally, 4 patients were steroid unre-
sponsive, 2 patients required steroid therapy, and 1 had
unknown outcome).
Almost all of the mutations linked to DBA have been
found in genes coding for ribosomal proteins (RPs).14
These RPs include: eS7 (RPS7), uS8 (RPS15A), eS10
(RPS10), eS17 (RPS17), eS19 (RPS19), eS24 (RPS24), eS26
(RPS26), eS27 (RPS27), eS28 (RPS28), uS14 (RPS29), uL18
(RPL5), uL5 (RPL11), eL15 (RPL15), eL18 (RPL18), uL24
(RPL26), eL27 (RPL27), eL31 (RPL31), uL29 (RPL35) and
eL33 (RPL35A).15-28  The RPL15 gene has so far been
reported in one patient who carried a large monoallelic
microdeletion involving this gene.23 Non-RP genes
linked to DBA, albeit very rarely involved, are TSR2 and
GATA1.26,29 RP gene aberrations lead to haploinsufficien-
cy, and in many cases result in reduction in the respective
RP which impairs ribosome biogenesis, affecting both
the processing pathways of pre-rRNA maturation and
the assembly of the large or small ribosomal subunit.30,31
TP53 is a tumor suppressor protein and transcription fac-
tor that stabilizes in response to cell stress, such as DNA
damage or nucleolar stress induced by ribosome biogen-
esis defects.32,33 Depending on the level of stress, stabi-
lized TP53 will induce cell arrest, DNA repair, senes-
cence and/or apoptosis. This pathway has been promi-
nently implicated in the pathogenesis of DBA, with a
number of studies suggesting that TP53 stabilization lies
at the heart of the loss of erythroid progenitor cells in
DBA bone marrow.34-36 In addition to activating apopto-
sis, DBA-linked RP gene mutations can impair cellular
differentiation, alter the landscape of mRNAs on ribo-
somes, and induce autophagy.36-38  
Therapy in DBA depends on the severity of anemia and
on the response to oral glucocorticosteroids (GCS). GCS-
non-responders receive chronic blood transfusions or can
undergo hematopoietic stem cell transplantation (HSCT)
which is often delayed because patients can achieve treat-
ment independence.39 For unknown reasons, 20% of all
DBA cases can become independent of steroid treatment
and/or blood transfusions by the age of 25 years.39,40 To
date, however, there are no predictive genetic markers
that could improve decision making for timely HSCT.
Given the significant risks that are associated with
HSCT,41 especially if a matched sibling donor is not avail-
able, such predictive markers would be very valuable.
Here we describe 6 DBA cases associated with muta-
tions in ribosomal protein gene RPL15. These patients
display an unexpectedly high rate of hydrops fetalis and
treatment independence, pointing to a new genotype-
phenotype correlation in DBA which could be important
for risk stratification. 
Methods
Patients
Diagnosis of DBA was made based on typical features includ-
ing aregenerative anemia with erythroid hypoplasia.1 Written
informed consent was obtained from patients and/or parents
prior to inclusion in this study, which was performed in accor-
dance with the ethical standards of the Declaration of Helsinki.
The study was approved by the institutional ethics committee
(University of Freiburg, IRB n. 205/99 and n. 351/17). 
Cell culture
Lymphoblastoid cell lines (LCLs) were derived from Epstein-
Barr virus (EBV)-immortalization of peripheral mononuclear
cells isolated from whole blood using Ficoll (GE Life Sciences)
and grown in RPMI (Gibco) containing 10% fetal calf serum
(FCS), 1% L-glutamine, and 1% penicillin/streptomycin, as pre-
viously described.42 
DNA sequencing and bioinformatics
Targeted Sanger sequencing was performed as previously
reported.43 Primer sequences are available upon request.
Pathogenicity of mutations, evolutionary conservation across
species, and the physicochemical difference between amino
acids were evaluated using standard prediction tools as outlined
in Online Supplementary Table S1. 
Details of pre-rRNA processing analysis, Northern blots,
polysome profiling, measurement of growth rate and de novo
protein synthesis are available in the Online Supplementary
Methods.
Erythroid red cell culture assays
Erythroid red cell culture assays were performed as previous-
ly described.36,44 Antibodies and stains for FACS analysis were
PC7 or PE conjugated CD34 (Beckman coulter, Brea, CA, USA),
APC conjugated CD36 (BD Biosciences San Jose, CA, USA), PE
conjugated α4 integrin (Miltenyi, Paris, France), APC conjugat-
ed Band 3 (kindly provided by Mohandas Narla’s lab, NYBC,
New York, USA), PE/Cy7 conjugated IL-3R (Miltennyi, Paris,
France), PE/Cy7 (PE)-coupled GPA (Life Technologies Carlsbad,
CA, USA), and DAPI (Sigma). FACS analysis was conducted on
a BD Biosciences Influx flow cytometer (BD Biosciences San
Jose, CA, USA). Data were analyzed using Kaluza software
(Beckman Coulter, Brea, CA, USA). Antibodies for western
blotting were TP53 (Sigma #5816), phospho-TP53 (Ser15, Cell
Signaling), p21 (Cell Signaling #2947), actin (Sigma #Ac-15), and
eL15 (Abcam #ab130992). Primers for real-time PCR used are as
follows: TaqMhupRPL15F:  CAGCCATCAGGTAAGCCAA-
GA; TaqMhuRPL15R: CAGCGGACCCTCAGAAGAAA;
TaqMhupp21F: TTGCTGCCGCATGGG, TaqMhup21R:
CCTTGTGGAGCCGGAGCT; TaqMhupactinF: CTGGAACG-
GTGAAGGTGACA;TaqMhupactinR: AAGGGACTTCCTG-
TAACAACGCA; TGTAGTGGATGGTGGTACAGTCAGA;
TaqMB2MhF:  GCGGCATCTTCAAACCTCC; TaqMB2MhR:
TGACTTTGTCACAGCCCAAGATA. Real-time PCR was per-
formed using the ABI 7900 Real Time PCR system and Taqman
PCR mastermix (Life Technologies Carlsbad, CA, USA).
Quantification of gene amplification was performed in dupli-
cate using DDCt method. The expression level of each gene was
normalized using the housekeeping genes: actin, and β2
microglobulin. 
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Results
Identification of novel RPL15 mutations in 6 patients
within EuroDBA registries
Approximately 30% of all registered DBA patients who
have been tested for mutations in the most common
DBA-linked genes (RPS19, RPL5, RPL11, RPS10, RPS26,
RPS7, RPS17, RPS24, and RPL35a) still do not have an
established genotype. Because a whole gene deletion of
RPL15 has been reported before in one DBA patient but
not in our cohorts,23 we used targeted Sanger sequencing
of RPL15 to determine if mutations in this gene could be
driving disease in patients without an established geno-
type. The national patient registries from EuroDBA part-
ners in Germany, France, Italy and Israel were included in
this study. As of November 2017, these cohorts represent
a total of 985 patients. A complete description of the his-
tory and composition of the EuroDBA consortium has
been recently published.45 Study outline and screening
strategy are illustrated in Online Supplementary Figure S1.
Four unrelated DBA patients from the German, and one
each from the French and Israeli registries were identified
carrying mutations in the RPL15 gene (NM_001253379.1),
which encodes ribosomal protein eL15/RPL15 (Figure 1A
and B). Out of the 6 RPL15-mutated patients, 3 unrelated
patients (P1-3) carried the same novel indel mutation
c.242dupA altering the tyrosine at position 81 to a stop
codon: p.Tyr81* (Table 1 and Online Supplementary  Table
S1). Patient 4 (P4) carried another stop-gain mutation in
RPL15 resulting in an even earlier protein truncation:
c.85C>T; p.Gln29*. The Exome Aggregation Consortium
(ExAC) reports that RPL15 is very intolerant to loss-of-
function mutations with no reported cases present in over
60,000 individuals (pLI score =0.96), strongly suggesting
the novel mutations p.Gln29* and p.Tyr81* found in our
patients are highly deleterious (Online Supplementary  Table
S1). In addition, the analysis of family trios revealed that
hotspot mutations arose de novo in two families (Table 1
and  Figure 1A), while one patient (P1/DE071) inherited
the mutation from her father who had been categorized as
RPL15 mutations in DBA
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Figure 1. Mutations in RPL15 are identified in patients with Diamond-Blackfan anemia (DBA). (A) Six unrelated pedigrees of individuals affected by DBA associated
with RPL15 mutations. All families have one DBA-affected individual who is also a mutation carrier, as indicated with filled squares (male) or circles (female).
Unaffected individuals are indicated by unfilled symbols. Unaffected mutation carriers are denoted by a dot symbol (). NA: unaffected family members who were
not investigated for the presence of mutations. Families 1-4 harbor heterozygous stopgain mutations in RPL15; families 5-6 carry heterozygous missense RPL15
mutations. (B) Schematic representation of human RPL15 depicting localization of the mutations identified in families 1-6. 
A
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a DBA silent carrier due to very high erythrocyte adeno-
sine deaminase (eADA) levels. The remaining two point
mutations c.29T>C; p.Leu10Pro (P5) and c.458A>C;
p.Lys153Thr (P6) affect highly conserved residues and,
based on results from in silico prediction, are probably
deleterious (Online Supplementary Table S1). Biomuta,
DMDM, the Exac/GnomAD databases, and NCBI do not
report any variants in the codon for Leu10. The GnomAD
population database reports one variant in Lys153
(Lys153Arg; rs370700905) identified in 33 out of 232840
total alleles. 
Genotype-phenotype association for truncating RPL15
mutations: severe hematologic phenotype and rapid
acquisition of treatment independence
All of the individuals with mutations in RPL15 present-
ed with typical bone marrow erythroid hypoplasia, ele-
vated eADA, and most of them presented with increased
fetal hemoglobin (HbF) levels (Table 1). Notably, hydrops
fetalis (considered the most severe hematologic pheno-
type of DBA) was associated only with truncating RPL15
mutations. The affected fetuses P2-4 required between
four and nine intrauterine transfusions (Table 1). One indi-
vidual (P2) with the p.Tyr81* hotspot mutation presented
with various physical malformations, while the dysmor-
phic features in other patients were less severe (Table 1).
Unexpectedly, all 3 patients carrying p.Tyr81* substitution
(P1-3) attained a rapid treatment independence both with
and without steroid treatment (Figure 2A), while the
fourth patient with the RPL15 mutation c.85C>T;
p.Gln29* responded to steroids; however, the therapy was
discontinued due to overt toxicity. 
Based on published observations of genetic revertant
mosaicism as a “repair mechanism” in other bone marrow
M.W. Wlodarski et al.
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Table 1. Clinical characteristics of patients with RPL15 mutations.
Pat/ ID RPL15 gene; Hematology and therapies Gestational age; Age and status Family
(sex) mutation malformations; other at last follow up history
1/DE071 c.242dupA; Onset: 3 months old; Hb 4.6g/dL 6.5 years, Father mutation 
(F) p.Tyr81* Lab: MCV↑, eADA↑ (925U/Iec), HbF normal normal Hb, carrier, eADA↑
Evolution: spontaneous recovery after 1 transfusion 37 weeks, IUGR no therapies  (1396U/Iec) but
at 6 months old. Relapse at 5.7 years (Hb 3.6g/dL),  clinically silent
achieved remission after short course of steroids
2/DE189 c.242dupA; Onset: prenatal (4 intrauterine transfusions) 34+1 weeks,  hydrops fetalis, ptosis, 5 years, Parents and
(M) p.Tyr81* Lab: MCV↑, eADA↑  (1526U/Iec), HbF  (6.6%) flat nose, deep set ears, normal Hb, sister wild type
Evolution: 4 transfusions (birth-16 months), intermittent AV-block, duplex no therapies
achieved remission after short course left kidney, hypogonadism, 
of steroids intersexual genitalia (46XY), microcephaly, 
left cerebellar hypoplasia,  developmental
disorder with mental retardation
and cerebral palsy
3/DE115 c.242dupA; Onset: prenatal (6 intrauterine transfusions), 35+6 weeks, hydrops fetalis, 16 years, Parents
(F) p.Tyr81* Lab: MCV↑, eADA↑ (1284U/Iec), HbF↑ (10.6%) IUGR, PFO normal Hb, wild type 
Evolution: 2 transfusions after birth, achieved no therapies
spontaneous remission at age of 4 months
4/DE202 c.85C>T; Onset: prenatal (9 intrauterine transfusions) 32+3 weeks, 18 years, Parents and
(M) p.Gln29* Lab: MCV↑, eADA↑ (2628U/Iec), HbF↑  (2%) hydrops fetalis, regular sibling
Evolution: after birth irregular transfusions, hypogammaglobulinemia, transfusions healthy
steroid-responsive (4-9 years), discontinued plantar warts (carrier status
due to toxicity, transfusion-dependent from age during steroid therapy unknown), 
of 9 years eADA/Hbf unknown
5/IL c.29T>C; Onset: 4 months old, Hb 5g/dL 27 weeks 2 years, Mother mutation
(F) p.Leu10Pro Lab: MCV↑, eADA and HbF unknown (placenta previa), steroids carrier: Hb, MCV 
Evolution: transfusion dependent, recently started none and HbF normal, 
steroids with good response eADA unknown
6/FR c.458A>C; Onset: 6 months old, Hb 7g/dL 41 weeks, low-set hair line; 22 years, Parents and
(M) p.Lys153Thr Lab: MCV normal, eADA unknown, HbF↑ (15%) growth retardation and regular sibling healthy 
Evolution: initially steroid-responsive, mental retardation transfusions (carrier status
transfusion dependent from age of 5 years unknown)
All patients presented with DBA-typical erythroblastopenia in bone marrow. Pat: patient number; ID: patient identifier in respective national registry; RP: ribosomal protein; F:
female, M: male; Hb: hemoglobin; Lab: supportive laboratory parameters; MCV: mean corpuscular volume; eADA: erythrocyte adenosine deaminase; Evolution: evolution of dis-
ease and therapies; ↑ elevated for age; HbF: fetal hemoglobin; Remission: treatment independence; IUGR: intrauterine growth restriction; PFO: persistent foramen ovale.
failure syndromes,46 we speculated that the hematologic
remission in our patients was attained via genetic rever-
sion (e.g. uniparental disomy). Sequencing of DNA in 
P1-3 either at multiple time points or after the acquisition
of treatment independence did not reveal any changes in
mutation load (Figure 2B).
Mutations in RPL15 recapitulate specific pre-rRNA
processing defects found in RP depleted cells
Mutations in DBA-linked RP genes result in haploinsuf-
ficiency of the encoded RP. Since the majority of RPs
incorporate into pre-ribosomal particles in a progressive
manner concurrently with pre-rRNA maturation, a lack of
one RP impairs pre-rRNA processing in an explicit way
that is reproducible in most cell types.47 Online
Supplementary Figure S2 illustrates the normal pre-rRNA
processing pathway that begins with a single transcribed
strand of 47S pre-rRNA that then undergoes a complex
series of cleavages and trimmings to ultimately result in
the mature 18S, 28S, and 5.8S strands of rRNA found in
ribosomes. To investigate the functional consequences of
the newly identified RP gene mutations reported here,
EBV-immortalized lymphoblast cell lines (LCLs) were gen-
erated and the pre-rRNA processing of these LCLs was
RPL15 mutations in DBA
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Figure 2. Longitudinal mutations in RPL15
are identified in individuals diagnosed with
Diamond-Blackfan anemia (DBA). (A) Clinical
evolution of P1-P3 carrying truncating hotspot
mutation RPL15 p.Tyr81*. Patient 1 manifest-
ed with DBA after birth and after one transfu-
sion achieved spontaneous remission at the
age of six months. A relapse occurred five
years later and after a short course of
steroids the patient attained treatment inde-
pendence. Patients 2 and 3 had a similar clin-
ical course with hydrops fetalis and prenatal
intrauterine transfusions, and achieved treat-
ment independence either spontaneously or
after one course of steroids. (B) Sanger
sequencing results of the recurring mutation
in RPL15 from initial diagnoses as well as
post remission. Arrows indicate the inserted A
nucleotide. FUP: follow up; BM: bone marrow;
PB: peripheral blood; LCL: lymphoblastoid cell
lines.
A
B
compared to HeLa cells depleted of eL15.
As previously reported,23 depletion of eL15 in HeLa cells
resulted in a decrease in 32S and 12S pre-rRNAs (Figure 3A
and C). This was accompanied by the accumulation of the
36S and 36S-C precursors, which are inconspicuous in
normal cells, and a concomitant drop in 32.5S pre-rRNA
(Figure 3B). In addition, these cells displayed lower levels
of 30S pre-rRNA and higher levels of 41S and 18S-E pre-
rRNAs (Figure 3A and C). This phenotype indicates that
depletion of eL15 affects cleavage of the ITS1 at site 2,
which promotes direct cleavage of early precursors at site
E and formation of 18S-E and 36S pre-rRNAs. The 36S
precursor is then trimmed by the 5’-3’ exoRNase XRN2 to
produce the 36S-C and 32.5S pre-rRNAs.48 Sucrose gradi-
ent analyses confirmed the efficiency of the eL15 siRNAs
in reducing the free 60S subunit peak and inducing the for-
mation of half-mers, as expected from the deficiency of an
RPL protein (Online Supplementary Figure S3). Consistent
with eL15 partial loss-of-function, an increase of 36S and
36S-C precursors was observed in the patient LCLs carry-
ing the eL15 p.Tyr81* variant (Figure 3B). In addition, both
cell lines displayed a marked increase of the amount of
18S-E precursors translating into a higher 18S-E/21S ratio,
similar to eL15-depleted cells (Figure 3A and C). This phe-
notype is similar to that previously observed in LCLs har-
boring a large heterozygous deletion in RPL15.23 
RPL15 mutations impair 60S ribosomal subunit 
formation, cell proliferation, and de novo protein 
synthesis
Defective processing of pre-rRNA in cells often results
in cells that are unable to fully form ribosomal subunits.
As such, pathogenic variants of RPs linked to DBA very
often impair biogenesis of ribosomal subunits in LCLs.37
Polysome profiling was performed to determine if the
observed pre-rRNA biogenesis defects resulted in
impaired biogenesis of large ribosomal subunits. Figure 4A
shows polysome profiles of LCL extracts derived from a
M.W. Wlodarski et al.
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Figure 3. Mutations in RPL15 recapitulate specific pre-rRNA processing defects found in eL15 depleted cells. (A) Northern blot analysis of siRNA-treated HeLa cells
or lymphoblastoid cell lines (LCLs) derived from individuals with Diamond-Blackfan anemia (DBA). Radiolabeled probes against ITS2 (top panel), ITS1 (middle panel),
18S or 28S (lower panel) rRNA sequences were used to blot 3µg total RNA isolated from cells. (B) Longer exposures of upper molecular weight pre-rRNA species
observed in the northern blots from (A). Intensity profiles of the lanes is shown in the right-hand boxes. (C) Quantification of rRNA precursors in siRNA-treated HeLa
cells (top) or LCLs (bottom) derived from individuals with DBA. The results of single experiments performed for each sample are displayed as multiple bars. Pre-rRNA
ratios are normalized by dividing by the mean of the control samples.
A B
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healthy individual or patients carrying the p.Tyr81* vari-
ant in eL15. As expected, the LCLs from the healthy indi-
vidual reveal an equivalent ratio of 40S to 60S peaks,
while the LCLs derived from patients reveal a substantial
reduction of 60S peaks compared to 40S peaks. These
results suggest the pre-rRNA defects depicted in Figure 3
go on to impair biogenesis of large 60S ribosomal sub-
units.
The impairment of ribosome biogenesis in cells can
slow the rate of protein synthesis and cell proliferation. RP
gene mutations linked to DBA are reported to slow the
rate of cell proliferation and increase apoptosis.36 In agree-
ment, we found that LCLs carrying the eL15 p.Tyr81* vari-
ant proliferated far more slowly than healthy control LCLs
(Figure 4B). Moreover, measurement of de novo protein
synthesis by Click-iT® labeling analysis revealed a severe
reduction in the synthesis rate of LCLs carrying the eL15
variant (Figure 4C and Online Supplementary Figure S4). 
Erythroid cell culture assays of primary RPL15
c.242dupA cells reveal severe proliferation defects,
differentiation delays, and TP53-related apoptosis 
Erythroid cell culture assays show that hematopoietic
progenitor cells can reveal reduced proliferation rates,
delayed differentiation, and increased TP53-induced
apoptosis in a manner that is largely dependent on which
RPL15 mutations in DBA
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Figure 4. RPL15 mutations impair cell proliferation, de novo protein synthesis, and 60S ribosomal subunit formation. (A) Representative (n=3) polysome profiles
of lymphoblastoid cell line (LCL) extracts derived from healthy individuals or individuals with Diamond-Blackfan anemia (DBA) carrying the RPL15 c.242dupA muta-
tion. The 40S small subunit, 60S subunit, 80S monosome, and polysomes are labeled. Arrows point to the reduced 60S peaks in cells with RPL15 mutations. (B)
Growth curve of LCLs derived from individuals with DBA or healthy controls over six days. Standard Deviations for healthy control-1 cells on days 1-5 are 2.6e4, 1.5e4,
3.8e4, 6.9e4, 1.0e5; healthy control-2 cells are 8.8e3, 3.0e4, 2.9e4, 7.5e4, 8.5e4; RPL15 c.242dupA-1 are 2.1e4, 1.9e4, 1.6e4, 2.3e4, 2.2e4; and RPL15
c.242dupA-2 are 9.5e3, 1.7e4, 1.7e4, 2.2e4, 2.5e4. (C) Measurement of the amount of de novo protein synthesis in 30 minutes in LCLs derived from healthy indi-
viduals or a DBA patient carrying the eL15 Tyr81* variant using Click-iT® analysis. 
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RP gene is haploinsufficient.36 We performed these assays
in CD34+ cells isolated from bone marrow mononuclear
cells (BM-MNC) of 2 patients with truncating RPL15
mutations p.Tyr81*. Compared to healthy control,
patients BM-MNC showed a higher rate of cell death and
apoptosis (Figures 5B and Online Supplementary Figure S5).
FACS analysis revealed CD36 downregulation and CD34
upregulation on both day 7 and day 9 in the Tyr81*
M.W. Wlodarski et al.
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Figure 5. Erythroid cell culture assays of primary RPL15 c.242dupA erythroid progenitor and precursor cells reveal severe erythroid proliferation defects, differen-
tiation delays, and TP53-related apoptosis. (A) Proliferation curve of erythroid cells isolated from CD34+ cells from peripheral blood of 2 individuals with Diamond-
Blackfan anemia (DBA) and an RPL15 mutation or a healthy control over nine days in liquid culture medium. (B) FACS analysis results of the percent of dead cells
or apoptotic cells staining positive for Annexin V on days 7, 10, and 13 after plating in red cell culture medium. (C) FACS analysis results on days 7 and 9 of the per-
cent of cells staining positive for CD36 and CD34. (D) FACS analysis results on days 7 and 9 of cells staining positive for IL3R and GPA. (E) FACS analysis results on
days 7 and 9 of cells staining positive for Alpha-4 and Band-3. (F) Real-time PCR results of the ratio between RPL15 mRNA and actin mRNA in cells. (G) Real-time
PCR results of the ratio between p21 mRNA and actin mRNA in cells. (H) Western blot analysis of cells from a healthy control or an individual with DBA and a mutation
in RPL15 using antibodies against phosphorylated TP53, p21, eL15, or actin on day 7. (I) Western blot analysis of cells from a healthy control or an RPL15 with DBA
and a mutation in RPL15 using antibodies against TP53 or actin on days 7 and 9.
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C
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mutant cells as compared to healthy controls (Figures 5C
and Online Supplementary Figure S5). In addition, Tyr81*
mutant cells retain a higher expression of the IL3 receptor
that is normally down-regulated in the erythroid lineage,
and express less erythroid-specific glycophorin A (GPA),
Band-3, or alpha-4 integrin compared to healthy control
cells (Figure 5D and E and Online Supplementary Figure S5).
Additionally, expression of RPL15 mRNA was lower
(Figure 5F) and of p21 mRNA higher in Tyr81* mutant
cells (Figure 5G). The observed p21 overexpression is like-
ly TP53-mediated, as supported by western blot analysis
confirming an increase in TP53 phosphorylation and
increased p21 protein expression (Figure 5H). Finally, TP53
protein stabilization was observed in Tyr81* mutant
patient cells (Figure 5I). 
Discussion
At present there are 19 RP genes associated with DBA,
representing almost one-quarter of the 80 cytoplasmic
RPs in human cells. Here, we describe a novel genetic
subgroup of DBA due to mutations in the RPL15 gene
and identify the truncating mutation c.242dupA;
p.Tyr81* as a recurrent genetic cause in 3 unrelated
patients. The experimental results show that LCLs carry-
ing the p.Tyr81* variant reveal an array of molecular
defects typically associated with a ribosomopathy phe-
notype. These include impaired pre-rRNA processing,
reduced 60S ribosomal subunit formation, a reduction in
de novo protein synthesis, and impaired cell proliferation.
Further, mutant LCLs phenocopied biological changes
observed in HeLa cells depleted of eL15. These results,
similar to previous reports that DBA-linked RP muta-
tions impair pre-rRNA processing, indicate that the
RPL15 mutations reported here are likely pathogenic and
result in haploinsufficiency. 
The altered ribosome biogenesis may explain the
observed reduction in global protein synthesis, substanti-
ating previous reports discussing altered translation of spe-
cific mRNAs in DBA-mutant cells as a key component of
disease pathogenesis.49,50 In support of this pathogenesis,
we also found that hematopoietic stem cells with the eL15
Tyr81* variant that were induced to differentiate into ery-
throcytes revealed a substantial decrease in the number of
erythroid colonies and delays in differentiation. These
findings, in addition to increased apoptosis, TP53 stabi-
lization, and p21 overexpression in RPL15-mutant
hematopoiesis, suggest that eL15 plays a critical role in
ribosome biogenesis and that the reduction of the protein
by genetic haploinsufficiency drives severe stress in the
nucleolus.
Hydrops fetalis arising from severe intrauterine anemia
is an uncommon manifestation of DBA with 10 cases
reported so far. The clinical outcome of these patients was
poor and, unexpectedly, no spontaneous remission was
observed. In contrast, 50% (3 of 6) of all patients with
RPL15 mutations reported in our study showed prenatal
manifestation with the necessity of intrauterine transfu-
sions. Remarkably, the hydrops cases were observed only
in the subgroup of patients carrying protein truncating
mutations p.Tyr81* and p.Gln29*, with prevalence of
hydrops reaching 75% (3 of 4). 
A substantial percentage of individuals with DBA spon-
taneously achieve treatment independence at some point;
however, the reasons for this remain elusive and no pre-
dictive biomarkers exist.39 In line with this, another unex-
pected finding was the rapid and sustained treatment
independence achieved within four to 16 months after
birth in all 3 unrelated DBA patients with the recurrent
p.Tyr81* mutation. Although Patient 1 relapsed five years
after achieving spontaneous remission, a short steroid
course was very effective and resulted in treatment inde-
pendence. These observations suggest that p.Tyr81*
mutation carriers can achieve treatment independence
with or without a previous course of steroids, and that a
genotype itself may be an important biomarker for the
expected clinical course. Our findings might help prospec-
tive clinical stratification to determine which individuals
are more likely to become treatment independent without
the need for HSCT. The reasons why the specific muta-
tion p.Tyr81* drives treatment independence remain
unknown and cannot be explained by a potential genetic
reversion, which was not observed in our patients. One
tempting speculation is that the remaining wild-type allele
compensates for the haploinsufficiency (e.g. by epigenetic
mechanisms) in the adult hematopoiesis, but the compen-
sation might not be present or sufficient in the fetus.
These findings warrant further studies on the future avail-
ability of more patient material.
In conclusion, our study establishes germline point
mutations in the RPL15 gene as novel genetic etiology of
DBA. Half of the individuals carrying these mutations
manifest with hydrops fetalis, a phenotype that is very
rarely observed in DBA patients. Finally, we establish that
a recurrent DBA genotype, eL15 p.Tyr81*, is linked to
treatment independence.
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